The weight-loss decade made GLP-1 a household acronym. The next chapter is quieter and, researchers argue, more interesting: therapies that act on the gut''s signaling system directly, with the aim of treating metabolic disease rather than shaping appetite.

Early trials are small. But the funding is not — and the shift marks a turn from a market measured in waistlines to one measured in wards.